Cardiovascular Risk Management with Tofacitinib

Patient Selection and Risk Assessment

The European Medicines Agency recommends that JAK inhibitors, including tofacitinib, should only be used in patients aged ≥65 years when no suitable alternatives are available, due to increased risk of major cardiovascular problems 1, 2, 3
Patients at increased risk of major cardiovascular problems, current or long-term past smokers, and those at increased risk of cancer should also be considered for alternative treatments 1, 2
The American College of Gastroenterology and the European Medicines Agency suggest that tofacitinib should not be used as first-line therapy in patients aged ≥50 years with cardiovascular risk factors when TNF inhibitors remain an option 1, 2, 4

Lipid monitoring should occur at 1-2 months after initiating tofacitinib, then every 6 months or annually, to manage dyslipidemia as a cardiovascular risk factor 5
Complete blood count with differential, comprehensive metabolic panel, and lipid panel should be monitored every 3 months, and clinical assessment for cardiovascular symptoms should be performed at each visit 6, 7
The American Heart Association recommends managing hypertension aggressively, optimizing lipid profile, and smoking cessation to reduce cardiovascular risk 1, 2

A risk-stratified approach should be applied, with high-risk patients (prior ASCVD or high 10-year ASCVD risk) only using tofacitinib if no alternatives are available, and intermediate-risk patients requiring enhanced cardiovascular monitoring 1, 2, 4
The European Society of Cardiology recommends optimizing modifiable cardiovascular risk factors before and during treatment, including managing hypertension, optimizing lipid profile, and smoking cessation 1, 2